Immatics NV
immatics.comWhat Do They Do?
Develops T-cell therapies and bispecific cancer drugs for people with solid tumors, including melanoma and other cancers.
20-F for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, a target expressed in more than 50…View ↗
Our PRAME franchise currently includes three TCR-based product candidates, two therapeutic modalities (cell therapy and bispecifics) and…View ↗
To maximize the tremendous opportunity of targeting PRAME, we have developed two modalities, cell therapy and bispecifics. Both modalities…View ↗
Who Are Their Customers?
Pharmaceutical and biotechnology companies collaborate with Immatics on cancer drug development. The company conducts research and development work and grants partners rights to develop and commercialize future products.
20-F for FY2025, filed Mar 5, 2026The Group currently earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies.…View ↗
Under the terms of these agreements, Immatics agreed to collaborate in the development, manufacture, and commercialization of cancer…View ↗
As part of these collaboration arrangements, Immatics grants exclusive licensing rights or options thereto for the development and…View ↗
How Are They Changing?
A narrower proprietary focus
The older report described a wider T-cell receptor pipeline, including donor-derived cell therapies and programs across several targets. The latest report centers its product pipeline on PRAME cell therapies and bispecifics, while also describing other proprietary and partnered candidates beyond PRAME.
20-F for FY2022, filed Mar 22, 2023 20-F for FY2025, filed Mar 5, 2026We are a clinical-stage biotechnology company dedicated to the development of T cell receptor (“TCR”)-based immunotherapies for the…View ↗
We are developing our targeted immunotherapy product candidates through two distinct treatment modalities: TCR-engineered autologous…View ↗
In addition to our autologous ACTengine product candidates we are also building an allogeneic platform (ACTallo) based on allogeneic (i.e.…View ↗
We are a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, a target expressed in more than 50…View ↗
Our PRAME franchise currently includes three TCR-based product candidates, two therapeutic modalities (cell therapy and bispecifics) and…View ↗
We are also driving innovation beyond PRAME with several proprietary and partnered product candidates in multiple indications.View ↗
Who Do They Compete With?
Competes with Iovance, Immunocore, Replimune, Obsidian Therapeutics, BioNtech, T-knife, Marker Therapeutics, Zelluna, Myrio Therapeutics, Etcembly, T-Scan, CDR Life, Neowise Biotechnology, Adaptimmune, Affini-T, Captain T-cell, T-scan Therapeutics, CorreGene, ImmunoScape, and Crossbow Therapeutics
20-F for FY2025, filed Mar 5, 2026Companies such as Iovance, Immunocore, Replimune and Obsidian Therapeutics are developing or commercializing products for the treatment of…View ↗
Loading...
